This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01326/identifier/pubchem-compound/
n12http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01326/identifier/pubchem-substance/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01326/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01326/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://www.rxlist.com/cgi/generic/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01326/identifier/chemspider/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/ontology/mesh/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01326/identifier/chebi/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01326/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01326/identifier/pharmgkb/
n8http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01326/identifier/kegg-compound/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01326
rdf:type
n3:Drug
n3:description
Cefamandole (INN, also known as cephamandole) is a broad-spectrum cephalosporin antibiotic. The clinically used form of cefamandole is the formate ester cefamandole nafate, a prodrug which is administered parenterally. Cefamandole is no longer available in the United States.
n3:group
approved
n3:halfLife
The half-life after an intravenous dose is 32 minutes; after intramuscular administration, the half-life is 60 minutes.
n3:indication
For the treatment of serious infections caused by susceptible strains of microorganisms.
owl:sameAs
n6:DB01326 n13:DB01326
dcterms:title
Cefamandole
adms:identifier
n15:456255 n16:46508882 n17:D02344 n18:PA448837 n19:DB01326 n20:C06879 n21:3480 n22:401748 n23:Cefamandole
n3:mechanismOfAction
Like all beta-lactam antibiotics, cefamandole binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefamandole interferes with an autolysin inhibitor.
n3:synonym
Cefamandolum Cephamandole Cefadole Cefamandol (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Cephadole Cefamandole nafate L-Cefamandole (6R,7R)-7-(R)-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid
n3:toxicity
Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting.
n3:proteinBinding
75%
n3:synthesisReference
Ta Sen Chou, Gary D. Zintgraff, "Process for preparing pure cefamandole from alkali metal and ammonium salts thereof." U.S. Patent US4115644, issued June, 1977.
n11:hasConcept
n12:M0003716
foaf:page
n10:cefamandole.htm
n3:IUPAC-Name
n4:271B6576-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B657C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B657B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6578-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6579-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B657A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6574-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3E7D-363D-11E5-9242-09173F13E4C5 n4:271B6572-363D-11E5-9242-09173F13E4C5 n4:271B6575-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6573-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:J01DC03
n3:H-Bond-Acceptor-Count
n4:271B3E72-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3E73-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B657D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B657E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3E70-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B657F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3E71-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
34444-01-4
n3:category
n3:Bioavailability
n4:271B3E78-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3E7A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3E7B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B3E7C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3E77-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3E76-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3E79-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6577-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3E74-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3E75-363D-11E5-9242-09173F13E4C5